Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05319730
Other study ID # 3475-06B
Secondary ID jRCT203122058220
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 16, 2023
Est. completion date September 20, 2028

Study information

Verified date May 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Email Trialsites@merck.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.


Description:

The master protocol is MK-3475-U06. As of Protocol Amendment 5, the Pembrolizumab Plus MK-4830 Plus Paclitaxel/Irinotecan arm and the Pembrolizumab Plus MK-4830 Plus Lenvatinib arm are no longer actively enrolling participants.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date September 20, 2028
Est. primary completion date November 7, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable ESCC. - Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy, that includes a platinum agent and previous exposure to an anti-PD1/PD-L1 based therapy. - Has an evaluable baseline tumor sample (newly obtained or archival) for analysis. - Has adequately controlled blood pressure (BP) with or without antihypertensive medications. - Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to =Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have =Grade 2 neuropathy are eligible. Exclusion Criteria: - Direct invasion into adjacent organs such as the aorta or trachea. - Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy. - Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing. - Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease. - Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention. - Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication. - Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy. - Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. - Active autoimmune disease that has required systemic treatment in past 2 years. - History of human immunodeficiency virus (HIV) infection. - History of Hepatitis B or known active Hepatitis C virus infection. - History of allogenic tissue/solid organ transplant. - Clinically significant cardiovascular disease within 12 months from first dose of study intervention. - Known GI malabsorption or any other condition that may affect the absorption of lenvatinib. (Not applicable to actively enrolling arms as of Amendment 5) - Has risk for significant GI bleeding such as a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization, significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization. (Not applicable to actively enrolling arms as of Amendment 5)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Paclitaxel
80-100 mg/m2 IV infusion, administered on days 1, 8, and 15 of every 28-day cycle.
Irinotecan
180 mg/m2 IV infusion, administered on day 1 of every 14-day cycle.
Biological:
Pembrolizumab
200 mg IV infusion, administered every Q3W.
MK-4830
800 mg IV infusion, administered Q3W up to 35 infusions.
Drug:
Lenvatinib
20 mg oral administration every day.
Biological:
Sacituzumab tirumotecan
4 mg/kg IV infusion on Days 1, 15, and 29 of each 42-day cycle.
Drug:
Antihistamine
Administered per product label.
H2 Receptor Antagonist
Administered per product label.
Acetaminophen (or equivalent)
Administered per product label.
Dexamethasone (or equivalent)
Administered per product label.

Locations

Country Name City State
Brazil Liga Norte Riograndense Contra o Câncer ( Site 4303) Natal Rio Grande Do Norte
Brazil Hospital Nossa Senhora da Conceição ( Site 4301) Porto Alegre Rio Grande Do Sul
Brazil ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300) São Paulo Sao Paulo
Chile Clínica las Condes ( Site 4403) Santiago Region M. De Santiago
Chile FALP-UIDO ( Site 4400) Santiago Region M. De Santiago
China Beijing Cancer hospital-Digestive Oncology ( Site 3500) Beijing Beijing
China Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511) Hangzhou Zhejiang
China Anhui Provincil Hospital South District ( Site 3501) Hefei Anhui
China First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506) Huai'an Jiangsu
China Shanghai Chest Hospital-Esophageal surgery department ( Site 3513) Shanghai Shanghai
China The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510) Xinxiang Henan
Germany Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804) Berlin
Germany Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801) Frankfurt Hessen
Italy Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200) Milan Lombardia
Italy Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Milano
Italy Ospedale San Raffaele-Oncologia Medica ( Site 3202) Milano Lombardia
Japan National Cancer Center Hospital ( Site 3700) Chuo-ku Tokyo
Japan Saitama Prefectural Cancer Center ( Site 3703) Ina-machi Saitama
Japan National Cancer Center Hospital East ( Site 3701) Kashiwa Chiba
Japan Shizuoka Cancer Center ( Site 3704) Nagaizumi-cho,Sunto-gun Shizuoka
Japan Aichi Cancer Center Hospital ( Site 3702) Nagoya Aichi
Korea, Republic of Asan Medical Center-Department of Oncology ( Site 3901) Seoul
Korea, Republic of Samsung Medical Center-Division of Hematology/Oncology ( Site 3900) Seoul
Norway Oslo universitetssykehus, Radiumhospitalet ( Site 4501) Oslo
Singapore National University Hospital ( Site 3800) Singapore South West
Switzerland Kantonsspital Graubünden-Medizin ( Site 4700) Chur Grisons
Switzerland Hôpitaux Universitaires de Genève (HUG) ( Site 4702) Genève Geneve
Taiwan Chang Gung Memorial Hospital at Kaohsiung ( Site 4003) Kaohsiung Niao Sung Dist Kaohsiung
Taiwan China Medical University Hospital ( Site 4007) Taichung
Taiwan Taichung Veterans General Hospital-Radiation Oncology ( Site 4008) Taichung
Taiwan National Cheng Kung University Hospital ( Site 4001) Tainan
Taiwan National Taiwan University Hospital ( Site 4000) Taipei
Taiwan Taipei Veterans General Hospital ( Site 4005) Taipei
Taiwan Chang Gung Medical Foundation-Linkou Branch ( Site 4006) Taoyuan
Thailand Faculty of Medicine Siriraj Hospital ( Site 4102) Bangkok Krung Thep Maha Nakhon
Turkey Ankara Bilkent City Hospital-Medical Oncology ( Site 3405) Ankara
Turkey Hacettepe Universite Hastaneleri-oncology hospital ( Site 3402) Ankara
Turkey Atatürk Üniversitesi-onkoloji ( Site 3416) Erzurum
Turkey TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3403) Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

Brazil,  Chile,  China,  Germany,  Italy,  Japan,  Korea, Republic of,  Norway,  Singapore,  Switzerland,  Taiwan,  Thailand,  Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) During Safety Lead-in Phase A DLT is defined as any drug-related AE according to the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. Up to approximately 3 weeks
Primary Number of Participants Experiencing Adverse Events (AEs) During Safety Lead-in Phase An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to approximately 3 weeks
Primary Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in Phase An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be presented. Up to approximately 3 weeks
Primary Objective Response Rate (ORR) ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented. Up to approximately 92 weeks
Secondary Progression-Free Survival (PFS) PFS is defined as the time from allocation to the first documented progressive disease (PD) as assessed by RECIST 1.1 or death due to any cause, whichever occurs first. PD is defined as =20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of =5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. Up to approximately 189 weeks
Secondary Duration of Response (DOR) For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. Up to approximately 189 weeks
Secondary Overall Survival (OS) OS is defined as the time from the date of allocation to death from any cause. Up to approximately 189 weeks
Secondary Number of Participants Experiencing at Least One Adverse Event (AE) During the Efficacy Phase An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Up to approximately 189 weeks
Secondary Number of Participants Who Discontinue Study Treatment Due to An AE During the Efficacy Phase An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Up to approximately 189 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06056336 - Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Phase 2
Suspended NCT04084158 - A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Not yet recruiting NCT05561699 - Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer N/A
Active, not recruiting NCT04543617 - A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Phase 3
Recruiting NCT06190782 - Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor Phase 3
Completed NCT05557955 - Identification of Breath Biomarkers in Esophageal Cancer
Recruiting NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Not yet recruiting NCT03766178 - Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02913066 - S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02399306 - Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma Phase 3
Completed NCT01605305 - Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer Phase 2
Not yet recruiting NCT05552651 - Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05520619 - Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002) Phase 2
Terminated NCT03251417 - Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT05990231 - Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy Phase 2
Recruiting NCT04644250 - Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Phase 2
Completed NCT02916511 - Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma Phase 2
Terminated NCT04032704 - A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Phase 2